發(fā)布時間：2018-08-30 13:33

【摘要】：目的:系統(tǒng)評價ACEIs和ARBs對腎移植受者血紅蛋白濃度的影響。方法:計算機(jī)檢索Medline、EMBase、Cochrane CENTRAL、中國生物醫(yī)學(xué)數(shù)據(jù)庫(CBM)、相關(guān)期刊論文(CNKI)、中文科技期刊全文數(shù)據(jù)庫(VIP)和萬方數(shù)據(jù)庫,檢索截止至2016年7月,納入腎移植受者接受ACEIs或ARBs治療與安慰劑或空白對照的隨機(jī)對照試驗(RCTs),評價納入RCTs的偏倚風(fēng)險,對同質(zhì)性結(jié)果進(jìn)行Meta分析,并評價結(jié)果的GRADE證據(jù)質(zhì)量等級。結(jié)果:共納入10個RCTs,受試者1503例。Meta分析結(jié)果顯示隨訪3月、6月、12月及12月以上,ACEIs或ARBs組血紅蛋白濃度均低于安慰劑或空白對照組,MD、95%CI和P值分別為:SMD=-1.50,95%CI(-2.10,-0.90);SMD=-0.40,95%CI(-0.77,-0.02),P=0.04;SMD=-0.79,95%CI(-1.20,-0.38),P=0.000 1;SMD=-0.72,95%CI(-0.84,-0.60),P0.000 01。4個結(jié)果的GRADE證據(jù)質(zhì)量等級分別為:中、低、低、中等質(zhì)量。結(jié)論:基于當(dāng)前證據(jù),RAS抑制劑可降低腎移植受者的血紅蛋白濃度。
[Abstract]:Objective: to evaluate the effect of ACEIs and ARBs on hemoglobin concentration in renal transplant recipients. Methods: Medline,EMBase,Cochrane CENTRAL, Chinese Biomedical Database (CBM), Chinese Journal Full-text Database (CNKI),) and Wanfang Database (VIP) were searched by computer. Randomized controlled trial (RCTs),) with ACEIs or ARBs therapy and placebo or blank control in renal transplant recipients included the risk of RCTs bias, Meta analysis of homogeneous results, and GRADE quality rating of the results. 緇撴灉:鍏辯撼鍏，

本文編號：2213227